Great Lakes Pharmaceuticals Raises Series B Early Stage Venture Capital Round
Cleveland, OH--Great Lakes Pharmaceuticals has raised a second round of early stage venture capital in a $3.1 million Series B equity financing, the company announced. Charter Life Sciences led the investment with participation by new investor Early Stage Partners and continuing investment from the Company's Series A investments.
The company will use the fund to complete a clinical study of its B-Lock™, an antimicrobial catheter lock solution.
"We are pleased with the recent equity financing, as it will position the company to conduct key clinical trials and international regulatory filings for this critical product," said Krzysztof Appelt, President and CEO of Great Lakes Pharmaceuticals. "We believe our antimicrobial lock solution can reduce life-threatening catheter-related bloodstream infections, improve patient care, and reduce overall health care costs." Read more...
Find Out More About ESP
Early Stage Partners Managing Director Mike Bunker manages the investment in Great Lakes Pharmaceuticals.